Company profile: Light Chain Bio
1.1 - Company Overview
Company description
- Provider of research and development of novel multi-specific antibodies that rely on their light chain for their function.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Light Chain Bio
NBE Therapeutics
HQ: Switzerland
Website
- Description: Provider of oncology therapies based on proprietary antibody-drug conjugates, including SMAC-Technology enzymatic conjugation for site-specific ADC manufacturing, Transpo-mAb mammalian cell display antibody discovery, a PNU-159682 anthracycline toxin payload platform, immune-oncology ADCs that activate CD8 cytotoxic T cells, and the ROR1-targeting NBE-002 candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NBE Therapeutics company profile →
Symphogen
HQ: Denmark
Website
- Description: Provider of recombinant polyclonal antibody drugs and platforms for disease treatment and prevention. Offers Symplex PCR cloning for antigen-specific antibodies, an antibody discovery and research platform focused on oncology and immuno-oncology, and CMC processes for manufacturing. Pipeline includes Sym013 (pan-HER antibody mixture) and Sym021 (anti-PD-1) with combinations Sym022 (anti-LAG-3) and Sym023 (anti-TIM-3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Symphogen company profile →
Alpheus Medical
HQ: United States
Website
- Description: Provider of a non-invasive sonodynamic therapy platform for solid body cancers that uses ultrasound to activate a cancer-targeting drug, including an SDT platform for outpatient treatment of recurrent high-grade gliomas and CV-01, an investigational drug-device using low-intensity, large-field ultrasound to target cancer cells across the brain hemisphere; CV-01 is in Phase 1 clinical trials for recurrent glioblastoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpheus Medical company profile →
X4 Pharmaceuticals
HQ: United States
Website
- Description: Provider of oral small molecule CXCR4 antagonists, including mavorixafor to mobilize white blood cells and improve immune function in patients with WHIM syndrome and certain chronic neutropenic disorders; runs a global Phase 3 WHIM trial with positive results and awaiting FDA approval, plus a Phase 2 trial in chronic neutropenic disorders with plans for Phase 3.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full X4 Pharmaceuticals company profile →
Algeta
HQ: Norway
Website
- Description: Provider of targeted oncology therapies based on an alpha-pharmaceutical platform, including radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algeta company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Light Chain Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Light Chain Bio
2.2 - Growth funds investing in similar companies to Light Chain Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Light Chain Bio
4.2 - Public trading comparable groups for Light Chain Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →